Misplaced Pages

Dacomitinib

Clinical data
Pronunciation	dak" oh mi' ti nib
Trade names	Vizimpro
Other names	PF-00299804
AHFS/Drugs.com	Monograph
MedlinePlus	a618055
License data	US DailyMed: Dacomitinib
Routes of administration	By mouth
ATC code	L01EB07 (WHO)
Legal status
Legal status	CA: ℞-only US: ℞-only EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	80%
Protein binding	98%
Metabolism	CYP2D6, CYP3A4
Metabolites	O-desmethyl-dacomitinib
Elimination half-life	70 hrs
Excretion	79% faeces, 3% urine
Identifiers
IUPAC name (2E)-N-{4--7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide
CAS Number	1110813-31-4
PubChem CID	11511120
IUPHAR/BPS	7422
DrugBank	DB11963
ChemSpider	9685914
UNII	2XJX250C20
KEGG	D09883 as salt: D10514
ChEBI	CHEBI:132268
ChEMBL	ChEMBL2105719
PDB ligand	1C9 (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID50149493
Chemical and physical data
Formula	C24H25ClFN5O2
Molar mass	469.95 g·mol
3D model (JSmol)	Interactive image
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
InChI InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+ Key:LVXJQMNHJWSHET-AATRIKPKSA-N

Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.

Dacomitinib has advanced to several Phase III clinical trials. In January 2014, results of the first trials were disappointing, with a failure to meet the study goals, but additional Phase III trials continued. In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.

Dacomitinib was approved for medical use in the United States in September 2018, in Japan in 2019, and in the European Union in 2019; for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation.

References

1. "Vizimpro Product information". Health Canada. 25 April 2012. Retrieved 29 May 2022.
2. "Summary Basis of Decision (SBD) for Verzenio". Health Canada. 23 October 2014. Retrieved 29 May 2022.
3. "Dacomitinib". NCI Drug Dictionary. National Cancer Institute, U.S. Department of Health and Human Services.
4. ^ Chustecka Z (27 January 2014). "Dacomitinib Fails in Pretreated Non-small Cell Lung Cancer". Medscape.
5. Taylor P (28 January 2014). "Blow to Pfizer as dacomitinib fails in lung cancer trials". pmlive.com.
6. "Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer". Pfizer Press Release. 27 January 2014.
7. Smith M (6 June 2017). "Dacomitinib Sets PFS Record in Phase III NSCLC Trial". MedPage Today.
8. Shirley M (December 2018). "Dacomitinib: First Global Approval". Drugs. 78 (18): 1947–1953. doi:10.1007/s40265-018-1028-x. PMID 30506139. S2CID 54034570.
9. "Vizimpro EPAR". European Medicines Agency (EMA). 5 June 2019. Retrieved 13 December 2019.

External links

• "Dacomitinib". Drug Information Portal. U.S. National Library of Medicine.

• Medicine

• Anilines
• Antineoplastic drugs
• CYP2D6 inhibitors
• 1-Piperidinyl compounds
• Drugs developed by Pfizer
• Quinazolines
• Orphan drugs